In 2009, STARmed embarked on a journey to improve patient lives around the world using minimally invasive thermal ablation technologies. We spearheaded ourselves in Thyroid RFA technologies and engineered the first thyroid-specific RF electrodes in 2009. In less than a decade, our innovation propelled us to become the global frontrunner in Thyroid RFA, with our technologies referenced in over 70% of the related clinical articles worldwide. Now, STARmed's influence reaches across 79 countries, holding more than 10 patents, and stands as a beacon of trust and excellence in the med-tech arena. Our product suite has diversified, addressing clinical challenges from uterine fibroids to conditions affecting vital organs like the liver, lung, and kidneys. Our objective is to maintain high levels of innovation, knowledge, and technical expertise to provide reliable solutions for patients comfort. As we venture into emerging businesses and burgeoning markets, our vision remains clear: to touch more lives and ensure their well-being. We will always continue to deliver our values and invest our passion and energy for the greater benefit of all patients.